Multiple sclerosis (MS) belongs to this category, since IL-1β is strongly implicated in this inflammatory, neurodegenerative disease [38], and IFN-β is still a classical first-line therapy [39], although rituximab (an anti-CD20 monoclonal antibody designed to induce B cell ablation) was shown recently as a promising option [40]. This evidence concerns the gene IFNB1 and multiple sclerosis.